Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 9.17
XON's Cash to Debt is ranked higher than
68% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. XON: 9.17 )
XON' s 10-Year Cash to Debt Range
Min: 9.17   Max: 118.37
Current: 9.17

9.17
118.37
Equity to Asset 0.67
XON's Equity to Asset is ranked higher than
73% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. XON: 0.67 )
XON' s 10-Year Equity to Asset Range
Min: -2.12   Max: 0.78
Current: 0.67

-2.12
0.78
Z-Score: 11.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -97.26
XON's Operating margin (%) is ranked higher than
72% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. XON: -97.26 )
XON' s 10-Year Operating margin (%) Range
Min: -1008.77   Max: -97.26
Current: -97.26

-1008.77
-97.26
Net-margin (%) -113.75
XON's Net-margin (%) is ranked higher than
70% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. XON: -113.75 )
XON' s 10-Year Net-margin (%) Range
Min: -1043.69   Max: -113.75
Current: -113.75

-1043.69
-113.75
ROE (%) -21.54
XON's ROE (%) is ranked higher than
76% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. XON: -21.54 )
XON' s 10-Year ROE (%) Range
Min: -172.6   Max: -21.78
Current: -21.54

-172.6
-21.78
ROA (%) -15.54
XON's ROA (%) is ranked higher than
77% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. XON: -15.54 )
XON' s 10-Year ROA (%) Range
Min: -61.45   Max: -12.55
Current: -15.54

-61.45
-12.55
ROC (Joel Greenblatt) (%) -215.92
XON's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. XON: -215.92 )
XON' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -804.38   Max: -200.16
Current: -215.92

-804.38
-200.16
» XON's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

XON Guru Trades in Q1 2014

Daniel Loeb 3,000,000 sh (+18.15%)
David Einhorn 1,379,014 sh (-37.58%)
» More
Q2 2014

XON Guru Trades in Q2 2014

Jean-Marie Eveillard 661,564 sh (New)
Daniel Loeb 2,900,000 sh (-3.33%)
David Einhorn 375,000 sh (-72.81%)
» More
Q3 2014

XON Guru Trades in Q3 2014

Jean-Marie Eveillard 790,364 sh (+19.47%)
Daniel Loeb 2,900,000 sh (unchged)
David Einhorn 197,278 sh (-47.39%)
» More
Q4 2014

XON Guru Trades in Q4 2014

T Boone Pickens 10,000 sh (New)
Daniel Loeb 2,900,000 sh (unchged)
David Einhorn Sold Out
Jean-Marie Eveillard 789,864 sh (-0.06%)
» More
» Details

Insider Trades

Latest Guru Trades with XON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Intrexon Corp

Daniel Loeb Comments on Intrexon Corporation - Jan 22, 2014

Equity Position: Intrexon Corporation (XON) ("Intrexon") We initially invested in Intrexon in 2011 in a private round and have continued to accumulate shares since its IPO in August 2013. We believe that Intrexon is an innovation leader in synthetic biology with a unique value proposition and proven leadership team. Most attractive to us is Intrexon's potential to transform multiple industries, including the health, food, and energy markets. 

Synthetic biology is an emerging discipline that applies engineering design principles to biologic systems. Broadly speaking, synthetic biology is about the design, modification, and regulation of gene programs to produce a desired outcome, such as the production of a novel antibody from a cell culture, the optimization of a specific gene trait in crops, or the amplification of wild type natural gas metabolism into an industrially feasible process. Over the past 15 years, Intrexon has developed deep expertise in synthetic biology as well as the adjacent fields of process optimization and data analysis to create a unique technology platform that enables the iterative, directed improvement of experimental design. 

To leverage its technology with collaborators, Intrexon has developed a unique business model that centers on Exclusive Channel Collaborations (ECCs) with partners. In exchange for providing access to their technology, Intrexon receives cost reimbursement (thus mitigating the need to raise additional external funds) and significant downstream economics. Because Intrexon's technology is scalable, its capaci ty to sign ECCs across multiple industries is limited only by the ambition of its partners. Indeed, to date, Intrexon has already signed over 15 ECCs including, notably, with Johnson & Johnson. Over the course of 2014 and beyond, we anticipate that Intrexon will sign multiple ECCs, creating a broad pipeline of projects and diversifying away from specific product risk.

Intrexon is led by Chairman and CEO Randal J. Kirk, one of the most successful healthcare leaders of all time. Kirk founded and led New River Pharmaceuticals until its acquisition by Shire, and led Clinical Data through the successful development and approval of the anti-depressant Viibryd before selling the company to Forest. 

While his track record of value creation speaks for itself, we especially like that Kirk has personally invested significantly in Intrexon's success through Third Security , which owns nearly 2/3 of Intrexon's shares outstanding. While Intrexon's business model may seem foreign to the healthcare industry, it reminds us of an undisputed technology leader: Qualcomm. Qualcomm out-licenses its CDMA technology and in return receives significant economics from its partners upon commercialization; the explosive growth of the global wireless communication market and its dominant position has driven Qualcomm to a $125 billion market cap. W hile we aren't saying that Intrexon will become a $125 billion company overnight, we will note the following two points: (1) the manipulation of DNA and gene sequences to produce beneficial outcomes is a well-established paradigm; (2) the global health, food, and energy markets dwarf the wireless communication market in size

 

 

From Daniel Loeb (Trades, Portfolio)'s Third Point fourth quarter 2013 commentary.

Check out Daniel Loeb latest stock trades

Ratios

vs
industry
vs
history
P/B 10.20
XON's P/B is ranked higher than
50% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. XON: 10.20 )
XON' s 10-Year P/B Range
Min: 3.71   Max: 13.1
Current: 10.2

3.71
13.1
P/S 54.30
XON's P/S is ranked higher than
51% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 37.39 vs. XON: 54.30 )
XON' s 10-Year P/S Range
Min: 6.16   Max: 69.97
Current: 54.3

6.16
69.97
EV-to-EBIT -56.47
XON's EV-to-EBIT is ranked higher than
87% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. XON: -56.47 )
XON' s 10-Year EV-to-EBIT Range
Min: -71   Max: -17.2
Current: -56.47

-71
-17.2
Current Ratio 3.68
XON's Current Ratio is ranked higher than
70% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. XON: 3.68 )
XON' s 10-Year Current Ratio Range
Min: 0.81   Max: 9.46
Current: 3.68

0.81
9.46
Quick Ratio 3.14
XON's Quick Ratio is ranked higher than
69% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. XON: 3.14 )
XON' s 10-Year Quick Ratio Range
Min: 0.81   Max: 9.46
Current: 3.14

0.81
9.46
Days Inventory 161.67
XON's Days Inventory is ranked higher than
85% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. XON: 161.67 )
XON' s 10-Year Days Inventory Range
Min: 244.37   Max: 244.37
Current: 161.67

Days Sales Outstanding 73.99
XON's Days Sales Outstanding is ranked higher than
80% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. XON: 73.99 )
XON' s 10-Year Days Sales Outstanding Range
Min: 0.89   Max: 73.99
Current: 73.99

0.89
73.99

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.69
XON's Price/Tangible Book is ranked lower than
54% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. XON: 18.69 )
XON' s 10-Year Price/Tangible Book Range
Min: 7.16   Max: 9.78
Current: 18.69

7.16
9.78
Price/Median PS Value 1.55
XON's Price/Median PS Value is ranked higher than
78% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. XON: 1.55 )
XON' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 1.05
Current: 1.55

0.32
1.05
Earnings Yield (Greenblatt) -1.80
XON's Earnings Yield (Greenblatt) is ranked higher than
80% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. XON: -1.80 )
XON' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.4   Max: 0
Current: -1.8

-2.4
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:I5X.Germany,
Intrexon Corp was founded in 1998. The Company designs, builds and regulates gene programs and cellular systems to enable the development of new and improved products and processes across a variety of market sectors, including Health, Food, Energy and Environment.The Company operates in one segment. It uses synthetic biology for the creation of distinct products developed in collaboration with partners. All of the Company's revenues are derived in the United States of America and all of its assets are located in the United States of America. The Company is subject to various federal, state and local environmental laws, rules and regulations, including those relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials and the health and safety of employees with respect to laboratory activities required for the development of products and technologies.
» More Articles for XON

Headlines

Articles On GuruFocus.com
Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

More From Other Websites
ZIOPHARM Announces Initiation of Phase 1 Study of Ad-RTS-IL-12 Gene Therapy in Patients With Brain... May 05 2015
Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 May 04 2015
Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 May 04 2015
Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and... May 04 2015
Steven Shallcross Named Chief Financial Officer of Synthetic Biologics May 04 2015
Fibrocell Science to Report First Quarter 2015 Financial and Operating Results, and Host Conference... May 01 2015
Intrexon to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Apr 30 2015
Intrexon to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Apr 30 2015
Synthetic Biologics to Host First Quarter 2015 Investor Conference Call Apr 30 2015
ICON Q1 Earnings Top, Revenues Lag; '15 View Updated - Analyst Blog Apr 29 2015
HealthEquity, Inc. (HQY) in Focus: Stock Moves 6.7% Higher - Tale of the Tape Apr 29 2015
ZIOPHARM Announces Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients With... Apr 27 2015
Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal... Apr 27 2015
INTREXON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 23 2015
Omnicare (OCR) Catches Eye: Stock Rises 5.2% - Tale of the Tape Apr 22 2015
Intrexon Completes Acquisition of Okanagan Specialty Fruits Apr 20 2015
Intrexon Completes Acquisition of Okanagan Specialty Fruits Apr 20 2015
Fibrocell Science to Present at World Orphan Drug Congress USA 2015 Apr 17 2015
Driving Sustainable Agriculture through Improved Qualities in Eucalyptus and Poplar Trees Apr 15 2015
Soligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric... Apr 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK